{"brief_title": "BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis", "brief_summary": "The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.", "condition": "Juvenile Rheumatoid Arthritis", "intervention_type": "Drug", "intervention_name": "Abatacept", "description": "Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly", "arm_group_label": "Abatacept - Open Label", "other_name": "Orencia", "criteria": "Inclusion Criteria: - Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis; - Current active arthritis; - Failed treatment with at least one disease modifying anti-rheumatic drug (DMARD); - Subjects must discontinue use of any DMARD other than methotrexate prior to the first dose of study medication Exclusion Criteria: - Presence of infection or history of frequent acute or chronic infections; - Joint replacement surgery required during the study or history of surgery on more than 5 joints; - Live vaccines within 3 months of the first dose of study medication; - Unresolved serious bacterial infection or chronic bacterial infection; - Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash, hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.", "gender": "All", "minimum_age": "6 Years", "maximum_age": "17 Years", "healthy_volunteers": "No", "id": "NCT00095173.xml"}